2026 Lipid Guidelines Beyond Statins: Non- Statin Agents to Manage Dyslipidemias
-
June 12, 2026
June 12, 2026
Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.
July 16, 2026
Nearly 90% of patients who met algorithmic criteria for postacute sequelae of SARS-CoV-2 infection had at least 1 chronic or potentially chronic condition requiring ongoing clinical management.
June 30, 2026